Cargando…

Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen

Middle East respiratory syndrome coronavirus (MERS-CoV) has infected at least 2040 patients and caused 712 deaths since its first appearance in 2012, yet neither pathogen-specific therapeutics nor approved vaccines are available. To address this need, we are developing a subunit recombinant protein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nyon, Mun Peak, Du, Lanying, Tseng, Chien-Te Kent, Seid, Christopher A., Pollet, Jeroen, Naceanceno, Kevin S., Agrawal, Anurodh, Algaissi, Abdullah, Peng, Bi-Hung, Tai, Wanbo, Jiang, Shibo, Bottazzi, Maria Elena, Strych, Ulrich, Hotez, Peter J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5860679/ https://www.ncbi.nlm.nih.gov/pubmed/29496347 http://dx.doi.org/10.1016/j.vaccine.2018.02.065

Ejemplares similares

Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

Calling for rapid development of a safe and effective MERS vaccine
por: Hotez, Peter J., et al.
Publicado: (2014)

Vaccine Development Against Middle East Respiratory Syndrome
por: Lee, Hai Yen, et al.
Publicado: (2016)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

Process Characterization and Biophysical Analysis for a Yeast-Expressed Phlebotomus papatasi Salivary Protein (PpSP15) as a Leishmania Vaccine Candidate
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

Quantification of the Middle East Respiratory Syndrome-Coronavirus RNA in Tissues by Quantitative Real-Time RT-PCR
por: Algaissi, Abdullah, et al.
Publicado: (2019)

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2016)

Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines
por: Du, Lanying, et al.
Publicado: (2016)

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
por: Xia, Shuai, et al.
Publicado: (2019)

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
por: Jiang, Shibo, et al.
Publicado: (2014)

Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection
por: Agrawal, Anurodh Shankar, et al.
Publicado: (2016)

Advances in mRNA and other vaccines against MERS-CoV
por: Tai, Wanbo, et al.
Publicado: (2022)

The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation
por: George, Parakkal Jovvian, et al.
Publicado: (2020)

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
por: Ma, Cuiqing, et al.
Publicado: (2014)

Current advancements and potential strategies in the development of MERS-CoV vaccines
por: Zhang, Naru, et al.
Publicado: (2014)

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus
por: Agrawal, Anurodh Shankar, et al.
Publicado: (2016)

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus
por: Tang, Jian, et al.
Publicado: (2015)

Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection
por: Jiang, Shibo, et al.
Publicado: (2015)

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2013)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2022)

Coronavirus vaccine-associated lung immunopathology-what is the significance?
por: Bottazzi, Maria Elena, et al.
Publicado: (2020)

COVID-19 vaccines: neutralizing antibodies and the alum advantage
por: Hotez, Peter J., et al.
Publicado: (2020)

The SARS-CoV-2 Vaccine Pipeline: an Overview
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

Elevated Human Dipeptidyl Peptidase 4 Expression Reduces the Susceptibility of hDPP4 Transgenic Mice to Middle East Respiratory Syndrome Coronavirus Infection and Disease
por: Algaissi, Abdullah, et al.
Publicado: (2019)

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design
por: Ma, Cuiqing, et al.
Publicado: (2014)

Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate
por: Chen, Wen-Hsiang, et al.
Publicado: (2017)

Receptor-binding domain-based subunit vaccines against MERS-CoV
por: Zhang, Naru, et al.
Publicado: (2015)

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
por: Zhou, Yusen, et al.
Publicado: (2019)

Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells
por: Du, Lanying, et al.
Publicado: (2009)

Recombinant protein vaccines, a proven approach against coronavirus pandemics
por: Pollet, Jeroen, et al.
Publicado: (2021)

Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain
por: He, Lei, et al.
Publicado: (2019)

Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread
por: Lu, Lu, et al.
Publicado: (2013)

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2018)

Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate
por: Chen, Wen-Hsiang, et al.
Publicado: (2021)

Retrovectors packaged in CHO cells to generate GLP-1-Fc stable expression CHO cell lines
por: Li, Jing, et al.
Publicado: (2019)

Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay
por: Algaissi, Abdullah, et al.
Publicado: (2019)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

(1)H, (15)N and (13)C backbone resonance assignments of the archetypal serpin α(1)-antitrypsin
por: Nyon, Mun Peak, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_88m1e2k48c72bj6i8pbcke84ep